Recent Updates
Recently added Catalysts

ALXN1920

Phase 2

Primary Membranous Nephropathy | Small molecule | Other |AstraZeneca PLC|Last Updated: Apr 22, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment30
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)PHASE2 RECRUITING 30 — — Sep 19, 2025Jul 9, 2027Apr 22, 202640 United States, Argentina +8
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change From Baseline in Proteinuria Based on 24-hour UPCR at Week 26
Baseline, Week 26
Secondary Endpoints
Change From Baseline in Proteinuria Based on 24-hour UPCR at week 12
Baseline and week 12
Change From Baseline in Proteinuria Based on Spot UPCR at Week 12 and week 26
Baseline, Week 12 and Week 26
Change From Baseline in Serum Albumin at Week 12 and week 26
Baseline, week 12 and Week 26
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ALXN1920EXPERIMENTALParticipants will receive ALXN1920 subcutaneous (SC) and background treatment of ACE/ARB and Rituximab.
PlaceboEXPERIMENTALParticipants will receive placebo subcutaneous (SC) and background treatment of ACE/ARB and Rituximab.
Interventions
NameTypeDescription
ALXN1920DRUGParticipants will receive ALXN1920 SC infusion.
PlaceboDRUGParticipants will receive Placebo SC infusion.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites40

Inclusion Criteria: * Participants who have a documented diagnosis of PMN, established by positive antiPLA2R antibody level (\> 20 RU/mL) at Screening, which must be confirmed by a central laboratory * Participants are willing to receive the background Standard of Care (SoC) * Participants at high ...

Countries:United StatesArgentinaAustraliaBrazilChinaFranceItalySpainTaiwanUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMMay 26, 2026NCT07157787primaryCompletionDate: changed
LOWMay 24, 2026NCT07157787studyFirstPostDate: changed